The potency of this material is not determined on a lot to lot basis. However, historical data indicate potency values of >900 ug/mg.
A3650
Amikacin hydrate
aminoglycoside antibiotic
Synonym(s):
N1-[(S)-4-Amino-2-hydroxybutyryl]kanamycin A
Sign In to View Organizational & Contract Pricing.
About This Item
Empirical Formula (Hill Notation):
C22H43N5O13 · xH2O
CAS Number:
Molecular Weight:
585.60 (anhydrous basis)
UNSPSC Code:
51281632
NACRES:
NA.85
PubChem Substance ID:
EC Number:
253-538-5
Beilstein/REAXYS Number:
1445422
MDL number:
Skip To
Product Name
Amikacin hydrate, aminoglycoside antibiotic
InChI key
DTSOZYYWEZJFSS-XTHCGPPUSA-N
InChI
1S/C22H43N5O13.H2O/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);1H2/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1
SMILES string
O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O
biological source
synthetic
form
powder
color
white to almost white
antibiotic activity spectrum
Gram-negative bacteria
mycobacteria
mode of action
protein synthesis | interferes
storage temp.
2-8°C
Quality Level
1 of 4
This Item | A1774 | A2324 | B5264 |
|---|---|---|---|
| mode of action protein synthesis | interferes | mode of action protein synthesis | interferes | mode of action protein synthesis | interferes | mode of action protein synthesis | interferes |
| antibiotic activity spectrum Gram-negative bacteria, mycobacteria | antibiotic activity spectrum Gram-negative bacteria, mycobacteria | antibiotic activity spectrum Gram-negative bacteria, Gram-positive bacteria, mycobacteria | antibiotic activity spectrum Gram-negative bacteria, Gram-positive bacteria, mycoplasma |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
| form powder | form powder or crystals | form powder | form powder or crystals |
| biological source synthetic | biological source synthetic | biological source synthetic | biological source - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. −20°C |
Application
Biochem/physiol Actions
Amikacin inhibits bacterial protein synthesis by binding to the 30S ribosome subunit and inducing mRNA misreading. It interferes with the translocation of tRNA from the A-site to the P-site.[3]
General description
Chemical structure: aminoglycoside
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
Packaging
5G
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M P Goren et al.
The Pediatric infectious disease journal, 8(5), 278-282 (1989-05-01)
A three-drug antibiotic regimen including vancomycin and amikacin has been recommended as effective treatment in clinical settings in which Gram-positive bacteremias are a serious problem. To determine if vancomycin potentiates the tubular proteinuria associated with amikacin therapy, we studied febrile
G J Alangaden et al.
Antimicrobial agents and chemotherapy, 42(5), 1295-1297 (1998-05-21)
An A1400G mutation of the rrs gene was identified in Mycobacterium tuberculosis (MTB) strain ATCC 35827 and in 13 MTB clinical isolates resistant to amikacin-kanamycin (MICs, >128 microg/ml). High-level cross-resistance may result from such a mutation since MTB has a
H W Horowitz et al.
Antimicrobial agents and chemotherapy, 45(3), 786-788 (2001-02-22)
Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named Ehrlichia phagocytophila. To expand our knowledge of the susceptibility of E. phagocytophila, we tested six New York State isolates for susceptibility to 12
Sophia B Georghiou et al.
PloS one, 7(3), e33275-e33275 (2012-04-06)
Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their accuracy, however, is dependent largely on the strength of the association between a specific mutation and
Hessel Van der Weide et al.
Antibiotics (Basel, Switzerland), 9(3) (2020-03-07)
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a "drug of last resort" warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative bacterial infections. In the current study
-
where can i find the assay potency of the drug?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service